Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes

 Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes

Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes

Shots:

  • The intense market competition leads Novo to focus direct-to-consumer campaign for Ozempic, a once weekly Injectable Type 2 diabetes
  • First sales through total diabetic care fell 5% y-o-y with 8% decline in profit
  • GLP-1 has shown bright spot in Novo Nordisk’s portfolio, with increase of sale 20% in US and 12% outside US

Click here to read full press release / article | Ref: Biopharmadive | Image: KFGO

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post